Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2016

Open Access 01-12-2016 | Letter

Common genetic susceptibility to DCIS and invasive ductal carcinoma

Authors: Victoria Sopik, Steven A. Narod

Published in: Breast Cancer Research | Issue 1/2016

Login to get access

Excerpt

In a recent issue of Breast Cancer Research, Petridis and colleagues report a failure to detect any genetic polymorphism which predisposes to ductal carcinoma in situ (DCIS) but not to invasive ductal carcinoma (IDC) or vice versa [1]. They genotyped 5067 cases of DCIS, 24,584 cases of IDC, and 37,467 non-cancer controls for 76 different single nucleotide polymorphisms (SNPs), each of which has been shown to be associated with breast cancer susceptibility in previous studies [2, 3]. They found no significant difference in the magnitude of the associations for DCIS and IDC for any of the 76 loci. From this, the authors conclude that the genes responsible for DCIS and IDC are, by and large, the same and that larger studies are required to determine if susceptibility loci specific to DCIS exist. …
Literature
1.
Petridis C, Brook MN, Shah V, Kohut K, Gorman P, Caneppele M, et al. Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Res. 2016;18(1):22.CrossRefPubMedPubMedCentral
2.
Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RC, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45(4):353–61.CrossRefPubMedPubMedCentral
3.
Milne RL, Burwinkel B, Michailidou K, Arias-Perez J, Zamora MP, Menendez-Rodriquez P, et al. Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Hum Mol Genet. 2014;23(22):6096–111.CrossRefPubMedPubMedCentral
4.
Sopik V, Nofechs-Mozes S, Sun P, Narod SA. The relationship between local recurrence and death in early-stage breast cancer. Breast Cancer Res Treat. 2016;155(1):175–85.CrossRefPubMed
5.
Narod S. Breast cancer: The importance of overdiagnosis in breast-cancer screening. Nat Rev Clin Oncol. 2016;13(1):5–6.CrossRefPubMed
Metadata
Title
Common genetic susceptibility to DCIS and invasive ductal carcinoma
Authors
Victoria Sopik
Steven A. Narod
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2016
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-016-0719-z

Other articles of this Issue 1/2016

Breast Cancer Research 1/2016 Go to the issue

Research article

Relationships between mammographic density, tissue microvessel density, and breast biopsy diagnosis

Review

Cancer stem cell metabolism

Research article

High mammographic breast density predicts locoregional recurrence after modified radical mastectomy for invasive breast cancer: a case-control study

Review

Breast cancer brain metastases: biology and new clinical perspectives

Research article

p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer

Review

Beyond breast density: a review on the advancing role of parenchymal texture analysis in breast cancer risk assessment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits